167 related articles for article (PubMed ID: 37216396)
21. Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): A systematic review and meta-analysis.
Mohapatra D; Gupta AK; Haldar P; Meena JP; Tanwar P; Seth R
Pediatr Hematol Oncol; 2023 Feb; 40(1):86-97. PubMed ID: 35616365
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z
Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390
[TBL] [Abstract][Full Text] [Related]
23. [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation].
Adam Z; Rehák Z; Koukalová R; Szturz P; Krejčí M; Pour L; Zahradová L; Moulis M; Kodet R; Nebeský T; Brejcha M; Adamová Z; Hájek R; Mayer J
Vnitr Lek; 2012 Jan; 58(1):62-71. PubMed ID: 22448704
[TBL] [Abstract][Full Text] [Related]
24. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction.
Bernard F; Thomas C; Bertrand Y; Munzer M; Landman Parker J; Ouache M; Colin VM; Perel Y; Chastagner P; Vermylen C; Donadieu J
Eur J Cancer; 2005 Nov; 41(17):2682-9. PubMed ID: 16291085
[TBL] [Abstract][Full Text] [Related]
25. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
[TBL] [Abstract][Full Text] [Related]
26. Gastrointestinal involvement in disseminated Langerhans cell histiocytosis (LCH) with durable complete response to 2-chlorodeoxyadenosine and high-dose cytarabine.
Choi SW; Bangaru BS; Wu CD; Finlay JL
J Pediatr Hematol Oncol; 2003 Jun; 25(6):503-6. PubMed ID: 12794533
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of BRAF-Inhibitor Therapy in BRAF
Hazim AZ; Ruan GJ; Ravindran A; Abeykoon JP; Scheckel C; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Bennani NN; Rech KL; Young JR; Shah MV; Goyal G; Go RS
Oncologist; 2020 Dec; 25(12):1001-1004. PubMed ID: 32985015
[TBL] [Abstract][Full Text] [Related]
28. Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis.
Eder SK; Schwentner R; Ben Soussia P; Abagnale G; Attarbaschi A; Minkov M; Halbritter F; Hutter C
Blood Adv; 2022 Feb; 6(3):970-975. PubMed ID: 34619771
[TBL] [Abstract][Full Text] [Related]
29. Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine.
Rodriguez-Galindo C; Kelly P; Jeng M; Presbury GG; Rieman M; Wang W
Am J Hematol; 2002 Mar; 69(3):179-84. PubMed ID: 11891804
[TBL] [Abstract][Full Text] [Related]
30. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
[TBL] [Abstract][Full Text] [Related]
32. [Cladribine for 13 cases refractory high-risk children Langerhans cell histiocytosis].
Hu T; Liu R; Li J; Cao J; Zhang L; Li J; Fan W; Zhong D; Shi X
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):985-9. PubMed ID: 25417874
[TBL] [Abstract][Full Text] [Related]
33. Inhibitor of BRAF
Smirnova SY; Al-Radi LS; Moiseeva TN; Gemdzhian EG; Yakutik IA; Julhakyan HL; Novikov VA; Galstyan GM; Sudarikov AB
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):427-430. PubMed ID: 33811006
[TBL] [Abstract][Full Text] [Related]
34.
Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
[TBL] [Abstract][Full Text] [Related]
35. Long-term follow-up of children with risk organ-negative Langerhans cell histiocytosis after 2-chlorodeoxyadenosine treatment.
Barkaoui MA; Queheille E; Aladjidi N; Plat G; Jeziorski E; Moshous D; Lambilliotte A; Kebaili K; Pacquement H; Leverger G; Mansuy L; Entz-Werlé N; Bodet D; Schneider P; Pagnier A; Lutun A; Gillibert-Yvert M; Millot F; Toutain F; Reguerre Y; Thomas C; Tazi A; Emile JF; Donadieu J; Héritier S
Br J Haematol; 2020 Dec; 191(5):825-834. PubMed ID: 32700439
[TBL] [Abstract][Full Text] [Related]
36. Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone.
Wang W; Ge J; Ma H; Lian H; Cui L; Zhao Y; Li Z; Wang T; Zhang R
BMC Pediatr; 2024 Jan; 24(1):1. PubMed ID: 38172736
[TBL] [Abstract][Full Text] [Related]
37. [BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis].
Tang X; Guo X; Sun LY; Ai Y; Yang X; Sun JJ; Wu JR; Gao J
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Apr; 20(4):290-294. PubMed ID: 29658453
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of Langerhans cells histiocytosis by cladribin reached long-term complete remission in 9 out of 10 adult patients].
Adam Z; Szturz P; Duraš J; Pour L; Krejčí M; Rehák Z; Koukalová R; Navrátil M; Hájek R; Král Z; Mayer J
Klin Onkol; 2012; 25(4):255-61. PubMed ID: 22920165
[TBL] [Abstract][Full Text] [Related]
39. Association between clinicopathologic characteristics and BRAF
Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
[TBL] [Abstract][Full Text] [Related]
40. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine.
Dhall G; Finlay JL; Dunkel IJ; Ettinger LJ; Kellie SJ; Allen JC; Egeler RM; Arceci RJ
Pediatr Blood Cancer; 2008 Jan; 50(1):72-9. PubMed ID: 17455311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
